» Articles » PMID: 27515804

Effects of Chronic Administration of the Phosphodiesterase Inhibitor Vardenafil on Serum Levels of Adrenal and Testicular Steroids in Men with Type 2 Diabetes Mellitus

Overview
Journal Endocrine
Specialty Endocrinology
Date 2016 Aug 13
PMID 27515804
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate whether long-term, chronic treatment with the phosphodiesterase-5 inhibitor vardenafil affects adrenal and testicular steroidogenesis in diabetic men, using liquid chromatography-tandem mass spectrometry. A longitudinal, prospective, investigator-started, randomized, placebo-controlled, double-blind, clinical-trial was carried out, enrolling 54 male patients affected by type 2 diabetes mellitus diagnosed within the last 5 years. In total, 26 and 28 patients were followed for 1 year and assigned to the study and placebo group, respectively. Progesterone, 17-hydroxyprogesterone, androstenedione, testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, corticosterone, 11-deoxycortisol and cortisol, were evaluated using liquid chromatography-tandem mass spectrometry. No differences were seen in sex testicular steroids between study and control group. As for the adrenal gland, steroids were considered according to the zona in which they are produced. No significant differences were seen in steroid produced in zona fasciculata. For the zona reticularis, dehydroepiandrosterone significantly decreased during treatment only in the study group (p = 0.007), with higher levels at visit 2 and 8 than other visits. The dehydroepiandrosterone sulfate/dehydroepiandrosterone ratio significantly increased during treatment only in the verum group. Considering the adrenal zona glomerulosa, corticosterone significantly changed among visits both in both groups (p < 0.001), with higher levels at visit 2 (p = 0.028), 8 (p = 0.003), and 10 (p = 0.044), i.e., in coincidence with the complete clinical and instrumental examination performed only at these visits according to the study protocol. Chronically administered vardenafil reduces dehydroepiandrosterone levels and increases dehydroepiandrosterone sulfate/dehydroepiandrosterone ratio as possible consequences of modulation of steroidogenic enzymes by tissue changes in cyclic adenosine monophosphate and cyclic guanosine monophosphate availability. A possibly stress-related increase in corticosterone is suggested for the first time.

Citing Articles

Do "testosterone boosters" really increase serum total testosterone? A systematic review.

Morgado A, Tsampoukas G, Sokolakis I, Schoentgen N, Urkmez A, Sarikaya S Int J Impot Res. 2023; 36(4):348-364.

PMID: 37697053 DOI: 10.1038/s41443-023-00763-9.


The efficacy of PDE5 inhibitors in diabetic patients.

Swiecicka A Andrology. 2022; 11(2):245-256.

PMID: 36367281 PMC: 10107754. DOI: 10.1111/andr.13328.


The "Hitchhiker's Guide to the Galaxy" of Endothelial Dysfunction Markers in Human Fertility.

Santi D, Spaggiari G, Greco C, Lazzaretti C, Paradiso E, Casarini L Int J Mol Sci. 2021; 22(5).

PMID: 33806677 PMC: 7961823. DOI: 10.3390/ijms22052584.

References
1.
Andric S, Janjic M, Stojkov N, Kostic T . Protein kinase G-mediated stimulation of basal Leydig cell steroidogenesis. Am J Physiol Endocrinol Metab. 2007; 293(5):E1399-408. DOI: 10.1152/ajpendo.00482.2007. View

2.
Demirbas D, Wyman A, Shimizu-Albergine M, Cakici O, Beavo J, Hoffman C . A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition. PLoS One. 2013; 8(8):e71279. PMC: 3743849. DOI: 10.1371/journal.pone.0071279. View

3.
Miller W . Molecular biology of steroid hormone synthesis. Endocr Rev. 1988; 9(3):295-318. DOI: 10.1210/edrv-9-3-295. View

4.
Das A, Durrant D, Salloum F, Xi L, Kukreja R . PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2014; 147:12-21. PMC: 4494657. DOI: 10.1016/j.pharmthera.2014.10.003. View

5.
Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M . Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004; 145(5):2253-63. DOI: 10.1210/en.2003-1699. View